US Flag logoAn official website of the United States government
PROSPR 2 - METRICS Cervical Cancer Restricted Use Dataset
PROSPR
Data Resource:  PROSPR
Point of Contact:  
NCI PROSPR Team,  
Project

About This Dataset
The MultilEvel OpTimization of the CeRvIcal Cancer Screening Process in Diverse Settings & Populations (METRICS) PROSPR II Research Center was designed to elucidate multilevel factors that hamper or facilitate the cervical cancer screening process and reduce disparities. METRICS has three data-contributing sites from diverse healthcare settings - an integrated county tax-supported public safety-net healthcare system; a not-for-profit integrated delivery system primarily represented by two sites; and a mixed-model healthcare system providing coverage to enrolled members in facilities that are owned and operated by the healthcare system and through providers, medical groups, and hospitals that are contracted to provide health care services. Sites collected 10 years of high-quality, comprehensive cervical cancer screening process data at the patient, provider, clinic/facility, and system levels using a rich array of electronic clinical information systems and other data sources. The estimated size of the combined cohort is ~1.1 million screened and unscreened females. This is the public use dataset.
Core Data Elements
Number of Cases
5,365
Case Sex
Female (5,365)
Case Age At Diagnosis
20 to 24 years (719); 25 to 29 years (1,651); 30 to 34 years (1,720); 35 to 39 years (1,276)
Case Race
Asian (202); Black or African American (783); More Than One Race (126); Other (298); White (3,764); Unknown (192)
Case Ethnicity
Hispanic or Latino (2,195); Not Hispanic or Latino (3,098); Unknown (72)
Case Disease Diagnosis
Adenocarcinoma / AIS (258); Cervical Cancer, Not Defined (574); Invasive Adenosquamous Carcinoma (8); Neoplasm (13); Other Cancer (8); Squamous Cell Carcinoma / CIS (4,504)
Case Tumor Site
Cervix (5,365)
Additional Data Elements
DATA REPOSITORY
WORST CYTOLOGY IN 12 MONTHS PRIOR TO CANCER DIAGNOSIS
Atypical Glandular Cells (AGC) (120);  
Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion (ASC-H) (587);  
Atypical Squamous Cells of Undetermined Significance (ASC-US) (692);  
High Grade Squamous Intraepithelial Lesion (HSIL) (1,523);  
Low-Grade Squamous Intraepithelial Lesion (LSIL) (519);  
Negative for Intraepithelial Lesion or Malignancy (NILM) (237);  
No Cytology/Missing/Insufficient (1,660);  
Suspicious for Cancer (27);  
WORST HPV RESULT IN 12 MONTHS PRIOR TO CANCER DIAGNOSIS
HPV 16/18+ (223);  
HPV Unknown (2,346);  
HPV+ (1,112);  
HPV- (58);  
No HPV Test (1,626);  
Charts
Female (5,365)
5,365Female